These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34711975)

  • 1. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy.
    Blazkova J; Gao F; Marichannegowda MH; Justement JS; Shi V; Whitehead EJ; Schneck RF; Huiting ED; Gittens K; Cottrell M; Benko E; Kovacs C; Lack J; Sneller MC; Moir S; Fauci AS; Chun TW
    Nat Med; 2021 Nov; 27(11):1893-1898. PubMed ID: 34711975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells.
    Hendricks CM; Cash MN; Tagliamonte MS; Riva A; Brander C; Llano A; Salemi M; Stevenson M; Mavian C
    Microbiol Spectr; 2022 Aug; 10(4):e0135322. PubMed ID: 35699458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.
    Wang CY; Wong WW; Tsai HC; Chen YH; Kuo BS; Lynn S; Blazkova J; Clarridge KE; Su HW; Lin CY; Tseng FC; Lai A; Yang FH; Lin CH; Tseng W; Lin HY; Finstad CL; Wong-Staal F; Hanson CV; Chun TW; Liao MJ
    N Engl J Med; 2019 Apr; 380(16):1535-1545. PubMed ID: 30995373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.
    Strongin Z; Micci L; Fromentin R; Harper J; McBrien J; Ryan E; Shenvi N; Easley K; Chomont N; Silvestri G; Paiardini M
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32350073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features.
    Bartsch YC; Loos C; Rossignol E; Fajnzylber JM; Yuan D; Avihingsanon A; Ubolyam S; Jupimai T; Hirschel B; Ananworanich J; Lauffenburger DA; Li JZ; Alter G; Julg B
    mBio; 2021 Mar; 12(2):. PubMed ID: 33688003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
    Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
    J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.
    Clarridge KE; Blazkova J; Einkauf K; Petrone M; Refsland EW; Justement JS; Shi V; Huiting ED; Seamon CA; Lee GQ; Yu XG; Moir S; Sneller MC; Lichterfeld M; Chun TW
    PLoS Pathog; 2018 Jan; 14(1):e1006792. PubMed ID: 29324842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.
    Andrabi R; Makhdoomi MA; Kumar R; Bala M; Parray H; Gupta A; Kotnala A; Thirumurthy V; Luthra K
    J Clin Immunol; 2014 May; 34(4):504-13. PubMed ID: 24682667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.
    Noel N; Peña R; David A; Avettand-Fenoel V; Erkizia I; Jimenez E; Lecuroux C; Rouzioux C; Boufassa F; Pancino G; Venet A; Van Lint C; Martinez-Picado J; Lambotte O; Sáez-Cirión A; Prado JG
    J Virol; 2016 Jul; 90(13):6148-6158. PubMed ID: 27122576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Neutralizing Antibodies in HIV-1 Patients on Antiretroviral Treatment for Over Ten Years.
    Cao W; Wang X; Li B; Lin L; Du Z; Zhao H; Zhang Y; Xu Z; Qiao Y
    Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a Novel Humanized Mouse Model To Investigate
    Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing CD8
    Warren JA; Clutton G; Goonetilleke N
    Front Immunol; 2019; 10():291. PubMed ID: 30863403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption.
    Esmaeilzadeh E; Etemad B; Lavine CL; Garneau L; Li Y; Regan J; Wong C; Sharaf R; Connick E; Volberding P; Sagar M; Seaman MS; Li JZ
    Sci Transl Med; 2023 May; 15(695):eabq4490. PubMed ID: 37163616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients.
    Avelino-Silva VI; Miyaji KT; Mathias A; Costa DA; de Carvalho Dias JZ; Lima SB; Simoes M; Freire MS; Caiaffa-Filho HH; Hong MA; Lopes MH; Sartori AM; Kallas EG
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):189-95. PubMed ID: 26361176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
    Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
    J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
    Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
    PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV controllers suppress viral replication and evolution and prevent disease progression following intersubtype HIV-1 superinfection.
    de Azevedo SSD; Delatorre E; Côrtes FH; Hoagland B; Grinsztejn B; Veloso VG; Souza TML; Morgado MG; Bello G
    AIDS; 2019 Mar; 33(3):399-410. PubMed ID: 30531316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.